Back to Search
Start Over
SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron
- Source :
- medRxiv, article-version (status) pre, article-version (number) 2, The Journal of Infectious Diseases, The Journal of infectious diseases, vol 225, iss 11
- Publication Year :
- 2021
- Publisher :
- Cold Spring Harbor Laboratory, 2021.
-
Abstract
- The wide spectrum of SARS-CoV-2 variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of the immune response to different spike protein versions. Here, we compare the neutralization of variants of concern, including B.1.617.2 (Delta) and B.1.1.529 (Omicron) in sera from individuals exposed to variant infection, vaccination, or both. We demonstrate that neutralizing antibody responses are strongest against variants sharing certain spike mutations with the immunizing exposure. We also observe that exposure to multiple spike variants increases the breadth of variant cross-neutralization. These findings contribute to understanding relationships between exposures and antibody responses and may inform booster vaccination strategies.<br />SUMMARY This study characterizes neutralization of eight different SARS-CoV-2 variants, including Delta and Omicron, with respect to nine different prior exposures, including vaccination, booster, and infections with Delta, Epsilon, and others. Different exposures were found to confer substantially differing neutralization specificity.
- Subjects :
- Antibodies, Viral
Medical and Health Sciences
Neutralization
2.1 Biological and endogenous factors
Immunology and Allergy
Viral
Aetiology
Neutralizing antibody
Neutralizing
Lung
B.1.617.2
biology
Brief Report
Biological Sciences
natural infection
Phenotype
Spike Glycoprotein
Vaccination
AcademicSubjects/MED00290
Infectious Diseases
Spike Glycoprotein, Coronavirus
Pneumonia & Influenza
antibody escape
Spike (software development)
Antibody
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
B.1.1.529
B.1.1.529 (Omicron)
immune exposure
Microbiology
Antibodies
Article
Vaccine Related
Immune system
Biodefense
Humans
SARS-CoV-2
Prevention
COVID-19
Pneumonia
neutralization
vaccination
B.1.617.2 (Delta)
Antibodies, Neutralizing
Coronavirus
Emerging Infectious Diseases
Good Health and Well Being
variant
Antibody Formation
Immunology
biology.protein
Immunization
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- medRxiv, article-version (status) pre, article-version (number) 2, The Journal of Infectious Diseases, The Journal of infectious diseases, vol 225, iss 11
- Accession number :
- edsair.doi.dedup.....f8c1afb09411fdcae85ae149d1022640
- Full Text :
- https://doi.org/10.1101/2021.09.08.21263095